High-dimensional (HD) flow cytometry allows researchers to perform deep phenotyping of immune cells at the single cell level with increased accuracy and sensitivity.  This technology enables complex pathway characterization and data integration for the identification of biomarkers used in immunotherapy.  WuXi AppTec offers a comprehensive panel of HD flow cytometry services, with more than 100 …Read More >

The contribution of the X-ray crystallography team from our WuXi AppTec site in Germany was acknowledged in a recent study published in the journal Cancer Discovery. In this study, the authors show that compound STX-478, an allosteric PI3Kα inhibitor, selectively targets prevalent PI3Kα helical- and kinase-domain mutant tumors. STX-478 demonstrated robust efficacy in human tumor …Read More >

OncoWuXi Express will continue to keep you informed about updates to our on-line tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we showcase our FaDu ATM KO tumor model. Introduction: As reported, several physiological processes, such as the production of reactive oxygen species during …Read More >

To support antitumor efficacy testing and address the challenges of clinical translatability, WuXi AppTec offers extensive panels of immune-avatar humanized mouse models. Our platform includes hPBMC, hHSC, and hNK humanized models with enabling studies from our platform of over 1,700 CDX and PDX models. These well-established models cover multiple cancer types, including breast, lung, liver, …Read More >

Patient-derived xenografts (PDXs) represent a powerful platform for cancer drug screening and biomarker discovery and are considered the gold standard of in vivo models for their proven clinical relevance to human disease. WuXi AppTec offers a comprehensive platform of more than 1,400 well-annotated PDXs across 30 cancer types. We also provide expanded in vitro, ex …Read More >

Cancer, globally recognized as a significant threat to public health, can be effectively controlled in its early stages through chemotherapy, targeted therapy, and immunotherapy, all of which inhibit tumor growth. However, an inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure. Unraveling the underlying mechanisms of resistance is pivotal in overcoming …Read More >

STAT proteins are key mediators of cellular immunity, proliferation, apoptosis, and differentiation.  STATs are known to play a role in the pathogenesis of many different diseases (including cancer) and the development of drugs directly or indirectly targeting STAT signaling has become a major focus for discovery teams.  WuXi AppTec offers a comprehensive platform of biophysical …Read More >

Review of SITC 2023 Annual Meeting The 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) was held this year in San Diego, CA, USA. As one of the most influential international conferences dedicated to cancer immunotherapy, SITC provides attendees with a cross-disciplinary educational and interactive platform. This meeting focuses on discussing and …Read More >

SITC Poster #59: Since the emergence of the COVID-19 pandemic, numerous nucleic-acid therapeutics have been approved for clinical use. Distinguished from conventional protein-targeted therapy, nucleic acid therapeutics offer the potential for sustained effects via gene modification or inhibition. In this study, we conducted a comprehensive evaluation of the activity and anti-tumor effects of PKN3-targeted siRNA …Read More >